Contact

Inveready bets on biotechnology, invests in Cuantum and AB-biotics in less than a month


, , , , ,
Integral service around a transaction
BY : Diego GutiérrezFebruary Fri, 2016
Inveready has started the year with a strong commitment to biotechnology. A few weeks ago we announced that it had invested in Oncostellae, and recently we have learned that it has invested in two more companies, in Ab-BIOTICS through its debt fund and in Cuantum through its Inveready Biotech II fund.

bio

 

Inveready enters AB-biotics

AB-Biotics , a Catalan company listed on the MAB, has received a loan of 600,000 euros from Inveready, through its fund Inveready ventures finance I, a venture capital fund specialising in debt that provides loans that are backed at 50% by the European EFSI fund in the framework of the Innovfin programme to support innovative companies.

This transaction is one of the first to be carried out through this fund, after the agreement signed on 1 February between the European Investment Fund (EIF) and Inveready Venture Finance, to provide 6.6 million in financing over two years to innovative technology companies in Spain, thus supporting the emerging Spanish entrepreneurial ecosystem.

With this loan, which has a repayment period of 18 months, AB-Biotics will finance the company's international growth and accelerate the market launch of different products.

The transaction with the fund provides that Inveready will have a call option on 86,957 shares in the fund. AB-Biotics 2.07 per share. This package represents about 0.91% of the capital.

Inveready invests in Cuantum

Inveready has invested through its Inveready Biotech II fund in €1.6M in Cuantum Medical Cosmeticsa biotech company founded in November 2015.

Inveready Innvierte Biotech II, a private equity fund managed by Inveready Technology Investment Group, has invested in Cuantum Medical Cosmetics, a biotech company founded in 2015 with the aim of developing and commercialising cyanoacrylate-based medical adhesive products, which already has a strong structure in Latin America and Asia.

This first round will allow Cuantum to deploy its commercial strategy at two levels: in the Business to Business market, Cuantum will commercialise monomers and cyanoacrylate formulations. In the Business to Consumer market, up to 10 new products will be launched over the next two years in the veterinary, cosmetic and medical adhesives sectors (OTC and Hospital channel).

2016, a good year for biotech according to Ysios Capital and Caixa capital risk funds

In an interview with Josep Lluís Sanfeliu , founding partner of Ysios Capital and José Antonio Mesa is the investment director of Caixa Capital RiscBoth agree that 2015 has been a good year for biotechnology in Spain and that 2016, with large-scale operations already underway, looks good.

Among the investment trends for 2016 we will see opportunities coming out of hospital science and a lot of activity in digital health, as well as continued investment in therapeutic areas such as cancer or cardiovascular, because the medical need is still there.

If you would like to receive funding, please contact us. Abra-Invest has a team of experts in alternative financing with experience in the biotechnology sector.

 Other posts that may interest you

Investors lose their fear of investing in biotechnology

Spanish biotech companies go public

October 2015: Funding for the biotech sector: InnoUp Farma and Oryzon Genomics and Mind The Byte

If you are looking for financing, contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Call + 34 946424142 or fill in the contact form.

The M&A Professionals

Meet our services

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu